Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003

Obstetrics and Gynecology

Volumn 108, Issue 1, 2006, Pages 33-40

  Hing, Esther ^a   Brett, Kate M ^b  

^a NCHS/Division of Health Care Statistics   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; CALCULATION; CONTROLLED STUDY; COVARIANCE; ESTROGEN THERAPY; FEMALE; HEALTH SURVEY; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MENOPAUSAL SYNDROME; OUTPATIENT DEPARTMENT; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; AMBULATORY CARE; CLINICAL PRACTICE; DRUG UTILIZATION; EPIDEMIOLOGY; MENOPAUSE; MIDDLE AGED; STATISTICAL MODEL; STATISTICS;

ADULT; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEALTH CARE SURVEYS; HUMANS; LOGISTIC MODELS; MENOPAUSE; MIDDLE AGED; OFFICE VISITS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROGESTINS; UNITED STATES;

EID: 33746868350     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000220502.77153.5a     Document Type: Article

References (27)

1. Brett KM, Reuben CA. Prevalence of estrogen or estrogen-progestin hormone therapy use. Obstet Gynecol 2003;102:1240-9.
2. Brett KM, Burt CW. Utilization of ambulatory medical care by women: United States, 1997-98. Vital Health Stat 2001;13:1-46.
3. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
5. Barrett-Connor E, Stuenkel CA. Hormone replacement therapy (HRT)-risks and benefits. Int J Epidemiol 2001;30:423-6.
6. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
7. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285:1489-99.
8. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
10. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983-8.
11. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
12. Hing E, Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2003 summary; No. 365. Hyattsville, MD: National Center for Health Statistics; 2005.
13. Sirken MG, Shimizu I, French DK, Brock DB. Manual on standards and procedures for reviewing statistical reports. Hyattsville, MD: National Center for Health Statistics; 1990.
14. Research Triangle Institute. SUDAAN User's Manual, Release 9.0. Research Triangle Park (NC): Research Triangle Institute; 2004.
15. Marsh JV, Brett KM, Miller LC. Racial differences in hormone replacement therapy prescriptions. Obstet Gynecol 1999;93:999-1003.
16. Stafford RS, Saglam D, Causino N, Blumenthal D. Low rates of hormone replacement in visits to United States primary care physicians. Am J Obstet Gynecol 1997;177:381-7.
17. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997;145:536-45.
18. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53.
19. Stafford RS, Saglam D, Causino N, Blumenthal D. The declining impact of race and insurance status on hormone replacement therapy. Menopause 1998;5:140-4.
20. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
21. Sawka AM, Huh A, Dolovich L, Papaioannou A, Eva K, Thabane L, et al. Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. J Obstet Gynaecol Can 2004;26:967-73.
22. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-32.
23. Barber CA, Margolis K, Luepker RV, Arnett DK. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002). J Womens Health (Larchmt) 2004;13:975-85.
24. Schonberg MA, Wee CC. Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice. J Womens Health (Larchmt) 2005;14:507-14.
25. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006;53:356-61.
26. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366:409-21.
27. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663-72.